Q4 FY2025 · ended Dec 31, 2025 · Revenue $0 · Filed Feb 24, 2026
Fulcrum Therapeutics, Inc. (FULC) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$16.1 million. As of Jun 30, 2026 it held $318.8 million in cash and investments and $5.3 million in total debt.
Revenue
$0
Net income
$-26.18M
-51.4% vs year-ago quarter
Operating cash flow
$-16.04M
-16.1% vs year-ago quarter
Free cash flow
$-16.15M
-16.3% vs year-ago quarter
EPS
$-0.34
-21.4% vs year-ago quarter
Dividend per share
None
Shares outstanding
76.30M
+41.1% vs year-ago quarter
Net cash
$313.56M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- FULC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1680581
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 |
| Operating income | -$29.3M | -$22.2M | -$22.7M | -$21.9M | -$19.8M |
| Net income | -$26.2M | -$18.9M | -$20.3M | -$19.6M | -$17.3M |
| Diluted EPS | -$0.34 | -$0.25 | $0.11 | -$0.31 | -$0.28 |
| Operating cash flow | -$16.0M | -$18.8M | -$16.8M | -$14.2M | -$13.8M |
| Free cash flow | -$16.1M | -$18.8M | -$17.0M | -$14.3M | -$13.9M |
| Total assets | $324.0M | $346.8M | $366.3M | $214.9M | $228.8M |
| Total liabilities | $13.3M | $13.5M | $17.3M | $16.5M | $14.5M |
| Stockholders' equity | $310.7M | $333.3M | $349.0M | $198.4M | $214.4M |
| Cash and investments | $318.8M | $333.3M | $352.3M | $200.6M | $214.1M |
| Total debt | $5.3M | $5.9M | $6.4M | $7.0M | $7.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale, Change in control, Officer or director change, Regulation FD disclosure
|
Aug 17, 2026 | Aug 16, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 10, 2026 | Aug 7, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 25, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 11, 2026 | Jun 5, 2026 |
| 8-K |
Current report
Exit or restructuring costs, Other events
|
Jun 4, 2026 | May 31, 2026 |
All 520 Fulcrum Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.